Donaldson Capital Management LLC Has $46.31 Million Stock Holdings in Cencora, Inc. $COR

Donaldson Capital Management LLC boosted its position in shares of Cencora, Inc. (NYSE:COR) by 1,955.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 137,099 shares of the company’s stock after purchasing an additional 130,430 shares during the period. Cencora accounts for approximately 1.5% of Donaldson Capital Management LLC’s portfolio, making the stock its 24th biggest position. Donaldson Capital Management LLC owned about 0.07% of Cencora worth $46,305,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of COR. Marshall Wace LLP increased its position in Cencora by 518.9% in the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after purchasing an additional 1,672,762 shares during the last quarter. Mizuho Markets Americas LLC lifted its holdings in shares of Cencora by 116.4% during the 3rd quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock valued at $66,506,000 after buying an additional 1,511,906 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Cencora by 528.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock valued at $461,250,000 after buying an additional 1,241,186 shares in the last quarter. Viking Global Investors LP grew its stake in shares of Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after buying an additional 1,013,913 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Cencora by 4.1% in the third quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock worth $7,311,810,000 after buying an additional 916,506 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

COR has been the topic of several recent research reports. Morgan Stanley set a $380.00 price objective on shares of Cencora in a research report on Tuesday, March 17th. Leerink Partners reissued an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Evercore restated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. upped their price objective on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Twelve equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $403.17.

Cencora Stock Down 0.1%

COR stock opened at $312.28 on Monday. The stock has a market capitalization of $60.75 billion, a price-to-earnings ratio of 37.53, a price-to-earnings-growth ratio of 1.46 and a beta of 0.68. The company has a 50-day moving average of $352.05 and a two-hundred day moving average of $341.12. Cencora, Inc. has a 52-week low of $267.40 and a 52-week high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The business had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same period in the previous year, the company posted $3.73 earnings per share. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

Insider Buying and Selling

In other news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the transaction, the chief executive officer directly owned 66,726 shares in the company, valued at $23,669,713.98. The trade was a 7.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.38% of the stock is currently owned by corporate insiders.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.